Literature DB >> 23002364

Pentoxifylline in hepatopulmonary syndrome.

Hamid Reza Kianifar1, Maryam Khalesi, Eftekhar Mahmoodi, Monavar Afzal Aghaei.   

Abstract

AIM: To determine the effects of pentoxifylline (PTX) on clinical manifestations and evaluate arterial blood gas data in hepatopulmonary syndrome (HPS) in children.
METHODS: In a pilot study of 10 children with chronic liver disease, who had HPS, 20 mg/kg/d PTX was administered for 3 mo. Clinical data and arterial blood gas parameters were evaluated at baseline, the end of the treatment period, and 3 mo after drug discontinuation.
RESULTS: Six patients could tolerate PTX, while four patients experienced complications. Among patients who could tolerate PTX, there was a significant increase in arterial oxygen pressure (PaO(2)) (P = 0.02) and oxygen saturation (SaO(2)) (P = 0.04) and alveolar-arterial oxygen gradient (P = 0.02) after 3 mo of treatment. Significant decreases in PaO(2) (P = 0.02) and alveolar-arterial oxygen gradient (P = 0.02) were also seen after drug discontinuation.
CONCLUSION: PTX may improve PaO(2), SaO(2) and alveolar-arterial oxygen gradient in the early stage of HPS.

Entities:  

Keywords:  Alveolar-arterial oxygen gradient; Arterial oxygen pressure; Child; Hepatopulmonary syndrome; Pentoxifylline; Therapy

Mesh:

Substances:

Year:  2012        PMID: 23002364      PMCID: PMC3447274          DOI: 10.3748/wjg.v18.i35.4912

Source DB:  PubMed          Journal:  World J Gastroenterol        ISSN: 1007-9327            Impact factor:   5.742


  27 in total

Review 1.  The hepatopulmonary syndrome: NO way out?

Authors:  A T Dinh-Xuan; R Naeije
Journal:  Eur Respir J       Date:  2004-05       Impact factor: 16.671

2.  Pentoxifylline attenuation of experimental hepatopulmonary syndrome.

Authors:  Junlan Zhang; Yiqun Ling; Liping Tang; Bao Luo; Balu K Chacko; Rakesh P Patel; Michael B Fallon
Journal:  J Appl Physiol (1985)       Date:  2006-11-16

Review 3.  The hepatopulmonary syndrome.

Authors:  David T Palma; Michael B Fallon
Journal:  J Hepatol       Date:  2006-07-25       Impact factor: 25.083

4.  Cost-effectiveness of screening for hepatopulmonary syndrome in liver transplant candidates.

Authors:  D Neil Roberts; Miguel R Arguedas; Michael B Fallon
Journal:  Liver Transpl       Date:  2007-02       Impact factor: 5.799

5.  Severe arterial hypoxemia in liver cirrhosis.

Authors:  Maarten K Ninaber; Jacobus B de Vaal; Oskar T Corsmit; Frans H M Cluitmans; Joost G de Leeuw; Frits Smit
Journal:  Respir Care       Date:  2009-03       Impact factor: 2.258

6.  Pentoxifylline therapy for hepatopulmonary syndrome: a pilot study.

Authors:  Lal Babu Gupta; Ashish Kumar; Ashish Kumar Jaiswal; Jamal Yusuf; Vimal Mehta; Sanjay Tyagi; Deepak K Tempe; Barjesh Chander Sharma; Shiv Kumar Sarin
Journal:  Arch Intern Med       Date:  2008-09-08

7.  Pentoxifylline improves short-term survival in severe acute alcoholic hepatitis: a double-blind, placebo-controlled trial.

Authors:  E Akriviadis; R Botla; W Briggs; S Han; T Reynolds; O Shakil
Journal:  Gastroenterology       Date:  2000-12       Impact factor: 22.682

8.  Methylene blue improves the hepatopulmonary syndrome.

Authors:  P Schenk; C Madl; S Rezaie-Majd; S Lehr; C Müller
Journal:  Ann Intern Med       Date:  2000-11-07       Impact factor: 25.391

9.  A pilot study to investigate the use of oxpentifylline (pentoxifylline) and thalidomide in portal hypertension secondary to alcoholic cirrhosis.

Authors:  A S Austin; Y R Mahida; D Clarke; S D Ryder; J G Freeman
Journal:  Aliment Pharmacol Ther       Date:  2004-01-01       Impact factor: 8.171

10.  Pulmonary dysfunction and hepatopulmonary syndrome in cirrhosis and portal hypertension.

Authors:  Søren Møller; Aleksander Krag; Jan L Madsen; Jens H Henriksen; Flemming Bendtsen
Journal:  Liver Int       Date:  2009-09-02       Impact factor: 5.828

View more
  8 in total

Review 1.  Hepatopulmonary syndrome: What we know and what we would like to know.

Authors:  Israel Grilo-Bensusan; Juan Manuel Pascasio-Acevedo
Journal:  World J Gastroenterol       Date:  2016-07-07       Impact factor: 5.742

Review 2.  Emerging hepatic syndromes: pathophysiology, diagnosis and treatment.

Authors:  Gaetano Bertino; Graziella Privitera; Francesco Purrello; Shirin Demma; Emanuele Crisafulli; Luisa Spadaro; Nikolaos Koukias; Emmanuel A Tsochatzis
Journal:  Intern Emerg Med       Date:  2016-06-07       Impact factor: 3.397

Review 3.  Hepatopulmonary Syndrome.

Authors:  Yong Lv; Daiming Fan
Journal:  Dig Dis Sci       Date:  2015-03-03       Impact factor: 3.199

4.  Hepatopulmonary Syndrome and Portopulmonary Hypertension: Current Status and Implications for Liver Transplantation.

Authors:  Kelley Weinfurtner; Kimberly Forde
Journal:  Curr Hepatol Rep       Date:  2020-07-11

Review 5.  Potential Clinical Targets in Hepatopulmonary Syndrome: Lessons From Experimental Models.

Authors:  Sarah Raevens; Michael B Fallon
Journal:  Hepatology       Date:  2018-11       Impact factor: 17.425

6.  SemFunSim: a new method for measuring disease similarity by integrating semantic and gene functional association.

Authors:  Liang Cheng; Jie Li; Peng Ju; Jiajie Peng; Yadong Wang
Journal:  PLoS One       Date:  2014-06-16       Impact factor: 3.240

Review 7.  Pharmacological treatment for hepatopulmonary syndrome.

Authors:  Ahad Eshraghian; Amir A'lam Kamyab; Seung Kew Yoon
Journal:  Biomed Res Int       Date:  2013-09-12       Impact factor: 3.411

8.  Refractory hypoxemia caused by hepatopulmonary syndrome: a case report.

Authors:  Morgen L Govindan; Kevin W Kuo; Maryam Ghadimi Mahani; Thomas P Shanley
Journal:  J Med Case Rep       Date:  2014-12-10
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.